The VLA2001 COVID-19 Vaccine - Valneva bets on travel-ready protection

The VLA2001 COVID-19 Vaccine sits in a cooled steel tray, clear liquid in small glass vials reflecting the harsh white light of the filling line in Saint-Herblain. A technician adjusts a valve, while Valneva CEO Thomas Lingelbach watches data scroll across a monitor.

Travel-focused inactivated vaccine

VLA2001 is Valneva’s inactivated whole-virus COVID-19 vaccine, developed to offer a more traditional platform for adult immunization, particularly in Europe and the UK. Unlike mRNA vaccines, it contains chemically inactivated SARS-CoV-2 virus combined with two adjuvants to strengthen immune response.

Valneva positions VLA2001 for adults who prefer established technologies and for health authorities looking for diversified pandemic tools, including for travel vaccination campaigns. The company emphasizes the familiar profile of inactivated vaccines, similar in principle to many long-standing travel vaccines against diseases like Japanese encephalitis.

Formulation and dosing details

VLA2001 uses an inactivated Delta-variant SARS-CoV-2 strain grown on Vero cells, then chemically inactivated to prevent replication while preserving antigenic structures. The formulation combines aluminum hydroxide and CpG 1018 as adjuvants to stimulate both antibody and cellular immune responses.

The vaccine is supplied as a ready-to-use liquid in multidose vials for intramuscular injection in the deltoid muscle. In its authorized indication in the UK, the primary series consists of two doses administered 28 days apart in adults 18 to 50 years. The product must be stored refrigerated at 2°C to 8°C, avoiding freezing.

Regulatory history and indications

Valneva received conditional marketing authorization for VLA2001 from the UK Medicines and Healthcare products Regulatory Agency (MHRA) in April 2022, following a pivotal Phase 3 trial comparing it with AstraZeneca’s Vaxzevria. The authorization covers adults aged 18 to 50 years who have not yet been vaccinated, or who require boosting based on national guidance.

The company earlier signed an advanced purchase agreement with the UK government but that contract was later terminated, prompting negotiations and a focus on other markets including Europe. The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in mid-2022, recommending authorization for adults 18 to 50, followed by a formal approval.

Clinical performance and safety profile

In the Phase 3 “Cov-Compare” study, VLA2001 demonstrated non-inferior neutralizing antibody titers compared with AstraZeneca’s adenoviral vector vaccine, and in some analyses showed higher geometric mean titers. Seroconversion rates were high, supporting its efficacy as a primary series for SARS-CoV-2.

Reactogenicity data in the trial indicated lower rates of injection site pain, fatigue and headache compared with Vaxzevria, suggesting a more tolerable profile for some adults. Serious adverse events were rare and balanced between groups, with no specific safety signal for inactivated whole-virus technology beyond known vaccine risks.

Manufacturing footprint and logistics

Valneva produces VLA2001 primarily at its manufacturing site in Livingston, Scotland, and its facility in Solna, Sweden, supported by quality control labs in Saint-Herblain, France. Stainless steel bioreactors, chillers and filtration units hum constantly, an industrial soundscape that underpins each filled vial.

The inactivated platform, combined with standard cold-chain requirements of 2°C to 8°C, simplifies storage for hospital pharmacies and travel clinics compared with ultra-cold mRNA products. Shipments move in refrigerated trucks and air cargo containers, an infrastructure Valneva already uses for other travel vaccines such as IXIARO against Japanese encephalitis.

Positioning among travel vaccines

CEO Thomas Lingelbach repeatedly stresses how VLA2001 complements Valneva’s established travel vaccine portfolio, which includes IXIARO and other specialties for travelers and military personnel. The COVID-19 shot gives the company a foothold in pandemic immunization while keeping a focus on mobility and border requirements.

For frequent flyers who already receive multiple travel shots, a COVID-19 vaccine based on an inactivated platform can feel familiar in both schedule and handling, mirroring long-used vaccines against polio or hepatitis A. That familiarity can be a selling point for travel clinics advising risk-averse patients or those skeptical of newer modalities.

Revenue impact and share context

In investor presentations, Valneva outlines how VLA2001 contributes to revenues alongside travel and specialty vaccines, although COVID-19 sales are sensitive to changing epidemiology and government procurement decisions. The product’s future role will depend on booster strategies and the appetite of health systems for diversified portfolios.

On Xetra, the Valneva SE share (ISIN FR0013280286) reflects expectations around this COVID-19 program, travel-immunization demand and the broader pipeline rather than any single shot.